Stock 867 CHINA MEDICAL SYSTEM HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials China Medical System Holdings Limited

Equities

867

KYG211081248

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:27 2024-07-12 am EDT 		5-day change 1st Jan Change
6.61 HKD +2.48% Intraday chart for China Medical System Holdings Limited -1.34% -52.24%
Jun. 25 China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China CI
Jun. 18 China Medical System Gets Drug Registration Certificate for Lesion Visualization Drug in China MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 24,871 18,009 26,071 26,593 30,844 14,973 - -
Enterprise Value (EV) 1 24,200 15,927 24,362 24,000 27,803 11,633 11,192 10,317
P/E ratio 12.7 x 7.12 x 8.68 x 8.17 x 12.8 x 8.57 x 7.42 x 5.4 x
Yield 3.15% 5.68% 4.63% 4.93% 3.11% 5.07% 5.54% 7.59%
Capitalization / Revenue 4.09 x 2.59 x 3.13 x 2.91 x 3.85 x 1.88 x 1.63 x 1.39 x
EV / Revenue 3.98 x 2.29 x 2.92 x 2.62 x 3.47 x 1.46 x 1.22 x 0.95 x
EV / EBITDA 9.45 x 5.36 x 7.23 x 6.35 x 9.34 x 5.29 x 4.32 x 2.86 x
EV / FCF 9.61 x 6.78 x 10.6 x 7.93 x 12.7 x 5.86 x 5.5 x 3.74 x
FCF Yield 10.4% 14.8% 9.48% 12.6% 7.86% 17.1% 18.2% 26.8%
Price to Book 2.63 x 1.63 x 2.04 x 1.82 x 1.99 x 0.93 x 0.86 x 0.78 x
Nbr of stocks (in thousands) 2,480,409 2,470,761 2,457,444 2,451,989 2,451,989 2,439,529 - -
Reference price 2 10.03 7.289 10.61 10.85 12.58 6.138 6.138 6.138
Announcement Date 3/31/20 3/16/21 3/15/22 3/16/23 3/27/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6,074 6,946 8,337 9,150 8,013 7,964 9,191 10,804
EBITDA 1 2,560 2,972 3,371 3,780 2,976 2,198 2,588 3,602
EBIT 1 2,356 2,763 3,151 3,552 2,746 2,010 2,382 3,396
Operating Margin 38.79% 39.78% 37.79% 38.82% 34.27% 25.24% 25.92% 31.44%
Earnings before Tax (EBT) 1 2,488 2,816 3,457 3,763 2,874 2,125 2,415 3,360
Net income 1 1,956 2,530 3,017 3,259 2,401 1,773 2,046 2,697
Net margin 32.2% 36.43% 36.19% 35.62% 29.96% 22.27% 22.26% 24.97%
EPS 2 0.7905 1.024 1.223 1.328 0.9792 0.7165 0.8268 1.137
Free Cash Flow 1 2,518 2,351 2,309 3,028 2,185 1,986 2,036 2,761
FCF margin 41.45% 33.84% 27.7% 33.1% 27.27% 24.94% 22.15% 25.56%
FCF Conversion (EBITDA) 98.35% 79.1% 68.5% 80.12% 73.43% 90.37% 78.67% 76.66%
FCF Conversion (Net income) 128.73% 92.89% 76.52% 92.92% 91% 112.01% 99.53% 102.35%
Dividend per Share 2 0.3154 0.4138 0.4910 0.5344 0.3917 0.3111 0.3398 0.4656
Announcement Date 3/31/20 3/16/21 3/15/22 3/16/23 3/27/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 3,109 3,108 3,838 3,843 4,494 4,448 4,703 4,610 3,403 3,807 4,166 4,566 4,631
EBITDA - - - - - - - - - - - - -
EBIT 1 - - - 1,634 1,517 1,822 1,730 1,873 873.5 1,093 1,126 1,281 1,348
Operating Margin - - - 42.52% 33.76% 40.97% 36.79% 40.62% 25.67% 28.71% 27.04% 28.06% 29.1%
Earnings before Tax (EBT) - - - - - - - - - - - - -
Net income - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - -
EPS - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/31/20 8/12/20 3/16/21 8/23/21 3/15/22 8/22/22 3/16/23 9/12/23 3/27/24 - - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 671 2,081 1,708 2,593 3,041 3,341 3,781 4,657
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,518 2,351 2,309 3,028 2,185 1,986 2,036 2,761
ROE (net income / shareholders' equity) 21.9% 24.7% 25.4% 23.8% 15.9% 11% 12.2% 16%
ROA (Net income/ Total Assets) 18% 21.2% 21.2% 19.4% 13.5% 9.42% 10.3% 12.7%
Assets 1 10,839 11,936 14,255 16,781 17,742 18,816 19,816 21,167
Book Value Per Share 2 3.820 4.460 5.190 5.950 6.330 6.620 7.130 7.820
Cash Flow per Share 2 1.030 1.090 1.010 1.450 1.020 0.6900 0.7100 1.070
Capex 1 340 341 185 525 318 630 687 774
Capex / Sales 5.61% 4.92% 2.22% 5.74% 3.97% 7.91% 7.47% 7.16%
Announcement Date 3/31/20 3/16/21 3/15/22 3/16/23 3/27/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for China Medical System Holdings Limited

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.138 CNY
Average target price
10.1 CNY
Spread / Average Target
+64.60%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CHINA MEDICAL SYSTEM HOLDINGS LIMITED Stock China Medical System Holdings Limited
-52.24% 2.07B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 867 Stock
  4. Financials China Medical System Holdings Limited